DelveInsight Blog
Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.
Baxter Introduced New Injectable Pharmaceuticals to US Market; Bayer and Hologic Collaborated to Deliver Contrast-Enhanced Mammography; Labcorp Received FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit; Onkos Surgical Won FDA De Novo Nod For Antibacterial-Coated Orthopedic Implants; Heartbeam Presented Positive Results On Its Artificial Intelligence Capabilities For Detecting Arrhythmias; Cognito Therapeutics Showed Positive Non-Invasive Neuromod Results
Baxter Introduced New Injectable Pharmaceuticals to US Market On April 11, 2024, the pharmaceutical portfolio of multinational medical goods corporation Baxter International Inc. was augmented with the introduction of five new injectable medications in the US market. The goods were made to fulfill essential demands in therapeutic domains like anti-hypertensive and anti-infective drugs. Among the new products is a ready-to-use injection of norepinephrine bitartrate in 5% Dextrose, which is now available in three strengths—including a brand-new 16 mg/250 mL option—for severe, acute hypotension. This is the first and only ready-to-use…
Enhancing Patient Care: Transitioning from Eculizumab to Ravulizumab in gMG Management
Eculizumab (SOLIRIS) and ravulizumab (ULTOMIRIS) are two approved therapies for the treatment for adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor antibody-positive. The findings presented by Alexion, AstraZeneca Rare Disease unveil a remarkable decline in Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) scores post-transition, showcasing the transformative prowess of ravulizumab in revolutionizing gMG care. Navigating the treatment landscape for gMG patients has been marked by significant advancements, including the introduction of complement component 5 inhibitors such as eculizumab (SOLIRIS) and ravulizumab (ULTOMIRIS). The transition from eculizumab…
Revolutionizing gMG Treatment: Efgartigimod’s Triumph in Curtailing Oral Corticosteroid Dependence
Efgartigimod (VYVGART/VYVGART Hytrulo) is a prescription medicine for the treatment of gMG in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive). It is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Despite numerous adverse effects, including osteoporosis, weight gain, diabetes, and increased susceptibility to infections, oral corticosteroids (OCS) are frequently employed in the management of myasthenia gravis symptoms by suppressing the immune response. Therefore, reducing or tapering OCS usage is crucial to mitigate these risks while…
-Agonist.png "Toll-like Receptors Agonist")
